Relationship between oral cinacalcet therapy with CRP and anemia in hemodialysis patients with secondary hyperparathyroidism


  • Saeed Hoseininia Department of Internal Medicine, Ardabil University of Medical Sciences, Ardabil, Iran
  • Sousan Mohammadi Kebar Department of Internal Medicine, Ardabil University of Medical Sciences, Ardabil, Iran
  • Somaieh Matin Department of Internal Medicine, Ardabil University of Medical Sciences, Ardabil, Iran
  • Saeed Sadeghieh-Ahari Department of Community Medicine, Ardabil University of Medical Sciences, Ardabil, Iran
  • Helia Salemi School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran



Cinacalcet, Inflammation, Anemia, Hemodialysis, Hyperparathyroidism


Background: Cinacalcet is one of the newest calcium mimetic drugs in the treatment of patients with parathyroid cancer, secondary hyperparathyroidism in adults with chronic kidney disease. Due to the possible association between the effect of Cinacalcet on C-reactive protein and the pathophysiology of anemia in end-stage renal disease patients. The aim of this study was to evaluate the effect of oral Cinacalcet on rate of CRP and anemia in ESRD patients with secondary hyperparathyroidism.

Methods: This descriptive cross-sectional study was done on all 40 hemodialysis patients over 18 years of age underwent hemodialysis for at least 6 months. The levels of C-reactive protein, phosphorus, calcium, parathyroid hormone, ferritin, Total iron binding capacity, iron, hemoglobin before the start of treatment and based on the routine dialysis ward were repeated once every three months and recorded in the, in the checklist. Also, age, sex, weight, underlying disease, duration of dialysis and duration of use and dose of Cinacalcet were entered. The results of these experiments were reviewed and analyzed before and after treatment with Cinacalcet.

Results: In these patients, after treatment with Cinacalcet, the amount of hemoglobin increased and the amount of inflammation decreased and these changes were significant in hemoglobin rate but not significant in CRP rate. The relationship between patients' weight and inflammation was significant.

Conclusions: Treatment with Cinacalcet in hemodialysis patients, at least in this study, could be increased hemoglobin and decreased CRP rate and can be a hypothesis for large analytical studies.


National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1-266.

Mitch WE. Chronic kidney disease. In: Goldman L, Ausiello DA, eds. 23rd ed. United States of America: Cecil Medicine; 2011:11-26.

Eiser C, Morse R. A review of measures of quality of life for children with chronic illness. Arch Dis Child. 2001;84:205-15.

Drug information for the health care professional, 27th ed. United States of America: Mermedex; 2007;1:816-9.

Ganesh NM, Ratanlal A, Venkat NK. HPLC method for estimation of cinacalcet in bulk and tablet dosage form. Am J Pharm Tech Res. 2015;5(1):26-32.

MacGregor MS, Boag DE, Innes A. Chronic kidney disease: evolving strategies for detection and management of impaired renal function. QJM. 2006; 99(6):365-440.

Mpio I, Boumendjel N, Karaaslan H, Arkouche W, Lenz A, Cardozo C, et al. Secondary hyperparathyroidism and anemia. Effects of a calcimimetic on the control of anemia in chronic hemodialysed patients, Pilot Study. Nephrol Ther. 2011;7:229-65.

KDIGO clinical practice guidelines for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2:288.

Bray C, Bell LN, Liang H, Haykal R, Kaiksow F, Mazza JJ. Erythrocyte Sedimentation rate and C-reactive protein measurements and their relevance in clinical medicine. BMC Med J. 2016;18(6):96-106.

Mohammadi KS, Maleki N, Sharghi A. The incidence rate, risk factors and clinical outcome of acute kidney injury in critical patients. Iranian J Public Health. 2016;47(11):1717.

Tanaka M, Yoshida K, Fukuma S, Ito K, Matsushita, K. Effects of secondary hyperparathyroidism treatment on improvement in anemia: results from the MBD-5D study. PloS one. 2016;11(10):e48-65.

Aktsiali M, Papachrysanthou T, Griveas I, Andriopoulos C, Sitaras P. Treatment with Cinacalcet in hemodialysis patients with severe secondary hyperparathyroidism, influences bone mineral metabolism and anemia parameters. Current Drug Ther. 2014;15(3):249-312.

Fusaro M, D’Angelo A, Naso A, Chiara FG, Miozzo D, Gallieni MC. Treatment with Calcimimetic (Cinacalcet) alters epoetin dosage requirements in dialysis patients: preliminary report. Renal Failure. 2011;33(7):732-67.

Elajnaf T, Iamartino L, Mesteri I, Müller C, Bassetto M, Manhardt T, et al. Nutritional and pharmacological targeting of the calcium-sensing receptor influences chemically induced colitis in mice. Nutrients. 2019;11(12):3072.

Priscilla P, Alan H, Darins L, Lanmason VN. Current approaches in the treatment of CKD mineral and bone disease. Kidney Int. 2007;16(4):1103-30.




How to Cite

Hoseininia, S., Kebar, S. M., Matin, S., Sadeghieh-Ahari, S., & Salemi, H. (2022). Relationship between oral cinacalcet therapy with CRP and anemia in hemodialysis patients with secondary hyperparathyroidism. International Journal of Basic & Clinical Pharmacology, 11(5), 364–367.



Original Research Articles